Clinical Characteristics and Outcomes Among STEMI Patients with Cardiogenic Shock At Abu Dhabi City

February 13, 2025 updated by: Babiker Mohamed Babiker Elsiraj, Abu Dhabi Health Services Company

Clinical Characteristics and Outcomes Among ST-elevation Myocardial Infarction (STEMI) Patients with Cardiogenic Shock At Abu Dhabi City

A retrospective study on the clinical characteristics and treatment outcomes of patients admitted with ST-elevation Myocardial Infarction (STEMI) complicated with cardiogenic shock (CS) during admission or CS development during their hospital stay for two tertiary hospitals in Abu Dhabi, UAE, from 2020-2024.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Cardiovascular disease (CVD) accounts for 40% of mortality in the UAE, which is higher than the global average. Long-term trends, incidence studies, and best practice guidance on Cardiogenic Shock (CS) with ST-elevation Myocardial infarction (STEMI) in the United Arab Emirates (UAE) and the Gulf Cooperation Council (GCC) are limited.

Through this retrospective study, investigators aim to identify treatment modalities and trends, hospitalization events, and patient demographics and comorbidities which lead to participant recovery or mortality in Sheikh Khalifa Medical City (SKMC) and Sheikh Shakhbout Medical City (SSMC) tertiary hospitals for patients admitted with STEMI and CS or developed CS after hospitalization with STEMI during January 2020-January 2024.[200-400 participants]. Data will be collected from eligible patients' electronic medical records (EMR).

Study Type

Observational

Enrollment (Estimated)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Alina Naeem, MBBS
  • Phone Number: 0097124102534
  • Email: alnaeem@seha.ae

Study Contact Backup

  • Name: Babiker Babiker Mohamed Babiker Elsiraj MB Elsiraj, MD
  • Phone Number: 0564972830
  • Email: Belsiraj@seha.ae

Study Locations

  • United Arab Emirates
      • Abu Dhabi, United Arab Emirates, 11001
        • Recruiting
        • Sheikh Khalifa Medical City (SKMC)
        • Contact:
        • Contact:
        • Contact:
          • Babiker MB Elsiraj, MD
        • Contact:
          • Abdulmajeed BS Alzubaidi, MD
        • Contact:
          • Mohammed El Khazendar, MD
        • Contact:
          • Yousef S Alabrach, MD
        • Contact:
          • Alina Naeem, MBBS
      • Abu Dhabi, United Arab Emirates, 11001
        • Recruiting
        • Sheikh Shakhbout Medical City (SKMC)
        • Contact:
        • Contact:
        • Contact:
          • Babiker MB Elsiraj, MD
        • Contact:
          • Abdulmajeed BS Alzubaidi, MD
        • Contact:
          • Mohammed El Khazendar, MD
        • Contact:
          • Yousef S Alabrach, MD
        • Contact:
          • Alina Naeem, MBBS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization were treated in Abu Dhabi city from January 2020 to January 2024.

Description

Inclusion Criteria:

  • Age more than 18.
  • STEMI complicated by cardiogenic shock.
  • Were hospitalized or treated at SSMC or SKMC for STEMI complicated by cardiogenic shock.
  • Patient admitted between January 2019 to March 2024.

Exclusion Criteria:

  • Age less than 18.
  • Shock patient not related to Myocardial infarction.
  • NSTEMI-related cardiogenic shock.
  • Patients who were not treated at SSMC or SKMC for the STEMI complicated by cardiogenic shock.
  • Patient not admitted between January 2019 to March 2024.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients with STEMI & Cardiogenic Shock
Patients with STEMI complicated by cardiogenic shock on admission or after hospitalization treated at SKMC & SSMC, Abu Dhbai

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Analyze STEMI patient with CS disease profile
Time Frame: 5 years
Comorbidities, demographical information, past medical history, morbidity
5 years
Incidence of CS-complicated AMI events
Time Frame: 5 years
The incidence of CS-complicated AMI events will show an increase over the years because of advanced diagnostic modalities and a clearer definition of CS.
5 years
Analyze treatment outcomes in the targeted population as per the patient profile
Time Frame: 5 years
Incidence of Mortality
5 years
Analyze STEMI patient with CS disease profile
Time Frame: 5 years
Incidence of Morbidity
5 years
Analyze treatment outcomes
Time Frame: 5 years
% of patients who were discharged
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Abu Dhabi Health Services Company

Collaborators

Sheikh Khalifa Medical City
Sheikh Shakhbout Medical City

Investigators

  • Study Chair: Abdulmajeed BS Alzubaidi, MD, Abu Dhabi Health Services Co. -SEHA
  • Principal Investigator: Babiker Babiker Mohamed Babiker Elsiraj MB Elsiraj, Sheikh Shakhbout Medical City

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2024

Primary Completion (Actual)

January 1, 2025

Study Completion (Estimated)

May 30, 2025

Study Registration Dates

First Submitted

May 13, 2024

First Submitted That Met QC Criteria

July 30, 2024

First Posted (Actual)

August 2, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 13, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SEHAResearch ID 747

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The plan is to share the clinical study report with all researchers. We will share the study protocol and case report form if further collaboration is decided while expanding our study.

IPD Sharing Time Frame

The data will be available for 5 years after the analysis is completed

IPD Sharing Access Criteria

REDCap or PI & Facility Permission

IPD Sharing Supporting Information Type

  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ST Elevation Myocardial Infarction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe